Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elvitegravir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 1.00 |
| ▸ | PLA2G4A | P47712 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 4/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elvitegravir SCHEMBL13225651 | 1.00 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL726251 | 1.00 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL29623981 | 1.00 | METTL3 (1.00) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL1050765 | 0.99 | METTL3 (0.98) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL1050769 | 0.99 | METTL3 (0.98) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL2280863 | 0.94 | METTL3 (0.89) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL4366707 | 0.94 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAATP53 | |
| Elvitegravir SCHEMBL31577400 | 0.94 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAATP53 | |
| SCHEMBL1104875 | 0.93 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAAEGFR | |
| SCHEMBL19829420 | 0.93 | METTL3 (0.88) | METTL3PLA2G4AMAPTGAAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3472 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| WO-2026102345-A1 | METHODS OF ADMINISTERING THE VOLTAGE-GATED POTASSIUM CHANNEL OPENER AZETUKALNER | XENON PHARMACEUTICALS INC. (CA) | 2026-05-15 | — | — | WO | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| WO-2007079260-A9 | METHODS FOR IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS | GILEAD SCIENCES INC (US) | 2007-08-30 | — | — | WO | claimed |
| WO-2007089030-A1 | USE OF 6-(3-CHLORO-2-FLUOROBENZYL)-1-[(2S)-1-HYDROXY-3-METHYLBUTAN-2-YL]-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID OR SALT THEREOF FOR TREATING RETROVIRUS INFECTION | JAPAN TOBACCO INC. (JP) | 2007-08-09 | — | — | WO | claimed |
| WO-2007079260-A1 | METHODS FOR IMPROVING THE PHARMACOKINETICS OF HIV INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-07-12 | — | — | WO | claimed |
| EP-1758581-A1 | COMBINATIONS COMPRISING A 4-ISOQUINOLONE DERIVATIVE AND ANTI-HIV AGENTS | Japan Tobacco, Inc. (JP) | 2007-03-07 | — | — | EP | claimed |
| EP-1636190-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | Japan Tobacco, Inc. (JP) | 2006-03-22 | — | — | EP | claimed |
| US-20060030710-A1 | Stable crystal of 4-oxoquinoline compound | SHIONOGI & CO., LTD. (JP) | 2006-02-09 | — | — | US | claimed |
| US-20050288326-A1 | Combination therapy | SHIONOGI & CO., LTD. (JP) | 2005-12-29 | — | — | US | claimed |
| WO-2005112930-A1 | COMBINATIONS COMPRISING A 4-ISOQUINOLONE DERIVATIVE AND ANTI-HIV AGENTS | JAPAN TOBACCO INC. (JP) | 2005-12-01 | — | — | WO | claimed |
| WO-2005113508-A1 | STABLE CRYSTAL OF 4-OXOQUINOLINE COMPOUND | JAPAN TOBACCO INC. (JP) | 2005-12-01 | — | — | WO | claimed |
| EP-1564210-A1 | 4-OXOQUINOLINE COMPOUNDS AND UTILIZATION THEREOF AS HIV INTEGRASE INHIBITORS | JAPAN TOBACCO INC. (JP) | 2005-08-17 | — | — | EP | claimed |